Mexico Cardiac Marker Testing Market (2026-2031)
The Mexico Cardiac Marker Testing Market was valued at $150.1 Million in 2026 and projected to reach to $222.7 Million by 2031, representing a compound annual growth rate of 8.2%. Mexico's cardiac marker testing market is positioned for steady expansion through 2031, supported by growing healthcare investments and rising cardiovascular disease prevalence.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Mexico Cardiac Marker Testing Market Trends and Insights
- This 8.2% compound annual growth rate reflects Mexico's increasing healthcare infrastructure investments and rising prevalence of cardiovascular diseases across the nation.
- Mexico's market expansion is driven by improved diagnostic capabilities, growing awareness of early cardiac detection, and expanding access to point-of-care testing in both urban and emerging healthcare facilities. The cardiac marker testing sector in Mexico is benefiting from demographic shifts and lifestyle changes that elevate cardiovascular risk factors among the population.
- Mexico's healthcare system modernization and integration of advanced diagnostic technologies are accelerating adoption of troponin, BNP, and myoglobin testing protocols.
- Between 2026 and 2031, Mexico's market is expected to capture increasing demand from hospitals, diagnostic laboratories, and primary care centers seeking reliable cardiac biomarker solutions to improve patient outcomes and reduce mortality rates..
Key Market Statistics
- CAGR (2026-2031) 8.2% CAGR
- Market Size, 2026 ~USD 150.1 Million
- Forecast, 2031 ~USD 222.7 Million
- Country Mexico
Mexico Cardiac Marker Testing Market Overview
Market Valuation Growth :
Mexico's cardiac marker testing market is valued at USD 150.1 million in 2026 and is projected to reach USD 222.7 million by 2031, representing a robust 8.2% CAGR over the forecast period.
Healthcare Infrastructure Expansion :
Mexico is experiencing significant investments in healthcare infrastructure, particularly in diagnostic capabilities and laboratory facilities, which directly supports the adoption of advanced cardiac marker testing technologies.
Rising Cardiovascular Disease Burden :
The prevalence of cardiovascular diseases in Mexico continues to increase, driven by lifestyle factors, aging population demographics, and chronic conditions like hypertension and diabetes, creating sustained demand for cardiac diagnostics.
Diagnostic Capability Enhancement :
Mexican healthcare providers are increasingly adopting improved diagnostic capabilities and point-of-care testing solutions, enabling faster cardiac marker detection and better patient outcomes in both urban and emerging healthcare settings.
Mexico Cardiac Marker Testing Market Dynamics
- The 8.2% CAGR reflects Mexico's commitment to strengthening diagnostic infrastructure and improving access to cardiac testing across both public and private healthcare sectors.
- Increased awareness of early cardiac disease detection and government initiatives to enhance healthcare quality are expected to drive market penetration. The market outlook remains positive as Mexican healthcare providers modernize laboratory capabilities and adopt advanced testing technologies.
- Demographic shifts toward an aging population and lifestyle-related risk factors will continue to elevate demand for cardiac markers.
- Strategic partnerships between international diagnostic companies and Mexican healthcare institutions are anticipated to accelerate market growth and improve testing accessibility in underserved regions..
Related Ecosystem
In Vitro Diagnostics
Medical Devices
Key Takeaways
- Mexico's cardiac marker testing market will grow from USD 150.1 million in 2026 to USD 222.7 million in 2031, representing an 8.2% CAGR.
- Mexico's healthcare modernization and rising cardiovascular disease prevalence are primary drivers of market expansion through 2031.
- Mexico's adoption of point-of-care testing and advanced diagnostic technologies is accelerating across hospitals and primary care centers.
- Mexico's market growth is supported by demographic shifts and lifestyle factors increasing cardiac risk among the population.
Cardiac Marker Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | OTHER CARDIAC BIOMARKERS (Biomarker Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 10.3% from 2026 to 2031 |
| Largest Segment | SINGLEPLEX ASSAY (Assay Format) |
| Market Size Base Year (Billions) | ~USD 5.55 (2026) |
| Revenue Forecast (Billions) | ~USD 9.06 (2031) |
| Segments Covered | Product, Technology, Type, Indication, Biomarker Type, Point Of Testing, Assay Format, End User |
Mexico Cardiac Marker Testing Market Report Segmentation
8 segment dimensions are covered across the global market.
By Product
- Instruments
- Reagents & Kits
By Technology
- Clinical Chemistry
- Immunoassay
- Immunoassays
By Type
- Chemiluminescence
- Contract Testing Laboratories
- Elisa
- Hospital Laboratories
- Immunofluorescence
- Lateral Flow Immunoassay
- Reference Laboratories
By Indication
- Acute Coronary Syndrome
- Atherosclerosis
- Congestive Heart Failure
- Ischemia
- Myocardial Infarction
By Biomarker Type
- Brain Natriuretic Peptide
- Creatinine Kinase-Mb
- High-Sensitivity C-Reactive Protein
- Homocysteine
- Myoglobin
- Other Cardiac Biomarkers
- Troponin I & T
By Point Of Testing
- Lab Tests
- Poc Tests
By Assay Format
- Multiplex Assay
- Multiplex Assays
- Singleplex Assay
- Singleplex Assays
By End User
- Academic Institutes
- Laboratory Testing Facilities
- Point-Of-Care Testing
MEXICO: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC INSTITUTES | 16.7 | 16.7 | 17.8 | 19.1 | 20.6 | 22.3 | 24.2 | 26.2 | 8 |
| LABORATORY TESTING FACILITIES | 140.2 | 138.5 | 146.8 | 156 | 166.3 | 178 | 191.1 | 205.4 | 6.9 |
| POINT-OF-CARE TESTING | 50.3 | 50.6 | 54.7 | 59.3 | 64.5 | 70.4 | 77.1 | 84.6 | 9.1 |
| TOTAL | 207.2 | 205.8 | 219.4 | 234.4 | 251.4 | 270.7 | 292.4 | 316.2 | 7.6 |
Target Audience
- Diagnostic Equipment Manufacturers : In vitro diagnostics and cardiac testing equipment manufacturers need Mexico market data to assess market size, identify distribution channels, understand local competition, and develop localized product strategies for this growing healthcare market.
- Healthcare Providers & Hospital Networks : Mexican hospitals, diagnostic laboratories, and healthcare networks require market insights to benchmark their cardiac testing capabilities, understand demand trends, and make informed investment decisions in diagnostic infrastructure.
- Pharmaceutical & Biotech Companies : Companies developing cardiac biomarkers and diagnostic reagents need Mexico-specific market analysis to evaluate commercial potential, identify partnership opportunities, and plan market entry strategies in this expanding segment.
- Healthcare Investors & Private Equity : Investment firms and healthcare venture capitalists need comprehensive Mexico market data to evaluate investment opportunities in diagnostic companies, healthcare providers, and medical technology ventures in the cardiac testing sector.
- Healthcare Consultants & Advisors : Management consulting firms and healthcare advisors require detailed Mexico market intelligence to support client strategy development, competitive analysis, and market entry planning for cardiac diagnostics businesses.
Key Companies in the Mexico Cardiac Marker Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ABBOTT LABORATORIES | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing hardware, consumables, and services),Life Sciences (instruments, reagents, and genomic medicines),Diagnostics (clinical instruments, consumables, and software), |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| THERMO FISHER SCIENTIFIC | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| BIO-RAD LABORATORIES | United States | Public Company | Life Science,Clinical Diagnostics, |
| BIOMéRIEUX SA | France | Public Company | Clinical microbiology (culture media, VITEK, VITEK MS, API, ETEST, BACT/ALERT),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EPISEQ),Immunoassay and sepsis (VIDAS, Hybiome CLIA), |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (needles, syringes, vascular access, sharps safety),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems), |
| DIASORIN SPA | Italy | Public Company | Immunodiagnostics – LIAISON XL/XS infectious and GI disease panels,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX respiratory, |
| REVVITY | United States | Public Company | Diagnostics (prenatal, newborn, infectious disease, autoimmune, specialty IVD),Life science reagents, assay platforms, and genomic workflows,Instruments, imaging, detection systems, and software, |
| TOSOH CORPORATION | Japan | Public Company | Basic chemicals (caustic soda, sodium bicarbonate, calcium hypochlorite, related chlor-alkali),Petrochemicals and polymers (VCM, PVC, polyethylene, EVA, synthetic rubber, functional polymers),Polyurethanes and related intermediates (MDI, HDI, polyisocyanates, polyols, PU resins), |
| QUIDEL CORPORATION | United States | Public Company | Labs (Clinical Chemistry & Immunoassay),Transfusion Medicine,Point of Care, |
| GUANGZHOU WONDFO BIOTECH CO., LTD. | China | Public Company | Rapid test kits (COVID-19, infectious disease, fertility, drug-of-abuse, tumor markers, STD),Immunofluorescence platform (Finecare FIA Meter X2 and related assays),Chemiluminescence platform, |
ABBOTT LABORATORIES
Abbott Laboratories is a major United States-based public company founded in 1888 with approximately 115,000 employees, operating as a diversified healthcare organization.
DANAHER CORPORATION
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees, operating across multiple industrial and life sciences sectors.
SIEMENS HEALTHINEERS AG
Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and healthcare solutions.
THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific is a United States-based public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.
BIO-RAD LABORATORIES
Bio-Rad Laboratories is a United States-based public company founded in 1952 with 7,450 employees, specializing in life science research and clinical diagnostics products.
BIOMéRIEUX SA
bioMérieux SA is a French public company founded in 1963 with 14,894 employees, focused on in vitro diagnostics and microbiology testing solutions.
BECTON, DICKINSON AND COMPANY
Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees, specializing in medical devices, diagnostics, and biosciences.
DIASORIN SPA
DiaSorin SpA is an Italian public company founded in 1968 with 3,242 employees, specializing in in vitro diagnostics and immunodiagnostic solutions.
REVVITY
Revvity is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.
TOSOH CORPORATION
Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees, operating across specialty chemicals, pharmaceuticals, and diagnostics sectors.
QUIDEL CORPORATION
Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees, specializing in rapid diagnostic testing solutions.
GUANGZHOU WONDFO BIOTECH CO., LTD.
Guangzhou Wondfo Biotech Co., Ltd. is a Chinese public company founded in 1992 with 2,443 employees, focused on in vitro diagnostic products and solutions.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise valuation data for Mexico's cardiac marker testing market (USD 150.1M in 2026) with verified 8.2% CAGR projections through 2031, enabling accurate business planning and investment decisions specific to this market.
- Competitive Landscape Intelligence : Understand Mexico-specific competitive dynamics, key players, market share distribution, and strategic positioning within the cardiac diagnostics sector to identify partnership and expansion opportunities.
- Regulatory & Healthcare Infrastructure Insights : Access detailed analysis of Mexico's healthcare regulations, diagnostic standards, reimbursement policies, and infrastructure development initiatives that directly impact market entry and product commercialization strategies.
- Customer Demand & Adoption Trends : Identify Mexico-specific customer segments, purchasing behaviors, technology adoption rates, and clinical preferences to tailor marketing strategies and product offerings for maximum market penetration.
- Risk Assessment & Growth Drivers : Evaluate Mexico-specific market risks, regulatory challenges, and growth catalysts including disease prevalence trends, demographic shifts, and healthcare spending patterns to inform strategic decision-making.
Frequently asked questions
What is the current size of Mexico's cardiac marker testing market?
Mexico's cardiac marker testing market is valued at USD 150.1 million in 2026 and is projected to reach USD 222.7 million by 2031.
What is the growth rate for cardiac marker testing in Mexico?
Mexico's cardiac marker testing market is expected to grow at a compound annual growth rate (CAGR) of 8.2% from 2026 to 2031.
What factors are driving growth in Mexico's cardiac marker testing market?
Mexico's market growth is driven by healthcare infrastructure modernization, rising cardiovascular disease prevalence, increased awareness of early cardiac detection, and expanding point-of-care testing access.
Which cardiac markers are most commonly tested in Mexico?
Mexico's healthcare facilities primarily test for troponin, B-type natriuretic peptide (BNP), and myoglobin as key cardiac biomarkers for diagnosis and patient management.
What healthcare settings are driving demand for cardiac marker testing in Mexico?
Mexico's demand for cardiac marker testing is driven by hospitals, diagnostic laboratories, emergency departments, and primary care centers seeking improved cardiac diagnostic capabilities.
RESEARCH METHODOLOGY
The objective of the study is to analyze the key market dynamics, including drivers, opportunities, restraints, challenges, and strategies of key players. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players. The competitive landscape of the cardiac marker testing market analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches are used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation have been used.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
BREAKDOWN OF PRIMARY INTERVIEW PARTICIPANTS
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = > USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
|
COMPANY NAME |
DESIGNATION |
|
Abbott Laboratories (US) |
Sales Manager |
|
F. Hoffmann-La Roche AG (Switzerland) |
Product Manager |
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cardiac marker testing market. These methods were also used extensively to estimate the sizes of various market subsegments. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the cardiac marker testing market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Cardiac marker testing refers to the measurement and quantification of biological parameters, such as enzymes, hormones, and proteins that are released into the bloodstream or show altered levels in response to cardiac conditions. These tests serve as indicators of the heart's physiological and pathophysiological status and are used for the early detection, risk stratification, and monitoring of cardiovascular diseases, including acute coronary syndrome (ACS), acute myocardial infarction (AMI), cardiac ischemia, and congestive heart failure (CHF).
Key Stakeholders
- Product Manufacturers, Distributors, and Suppliers
- Diagnostic Laboratories and Point-of-care Testing Centers
- Research Laboratories and CROs
- Ambulatory Testing Centers
- Contract Testing Laboratories
- Academic Universities and Medical Research Centers
- Research & Development (R&D) Centers
Report Objectives
- To define, segment, and forecast the cardiac marker testing market by product, technology, indication, biomarker type, point of testing, assay format, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
- To study the impact of AI on the market, along with the macroeconomic outlook for each region
Available customizations:
MarketsandMarkets offers the following customizations for this market report.
Country Information
- Additional country-level analysis of the cardiac marker testing market
Company profiles
- Additional five company profiles of players operating in the cardiac marker testing market.
Product Analysis
- Product matrix, which provides a detailed comparison of the product portfolio of each company in the cardiac marker testing market
Get the Full Cardiac Marker Testing Market Report
Full forecast, segment splits, and company analysis for all Cardiac Marker Testing Market.
- US Cardiac Marker Testing Market
- Canada Cardiac Marker Testing Market
- UK Cardiac Marker Testing Market
- Germany Cardiac Marker Testing Market
- France Cardiac Marker Testing Market
- Italy Cardiac Marker Testing Market
- Spain Cardiac Marker Testing Market
- China Cardiac Marker Testing Market
- Japan Cardiac Marker Testing Market
- India Cardiac Marker Testing Market
- Australia Cardiac Marker Testing Market
- South Korea Cardiac Marker Testing Market
- Brazil Cardiac Marker Testing Market
- Rest Of Europe Cardiac Marker Testing Market
- Rest Of Asia Pacific Cardiac Marker Testing Market
- Rest Of Latin America Cardiac Marker Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report